Erratum: The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma (Blood Cancer Journal (2011) 1 (e46) DOI:10.1038/bcj.2011.46);The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma

Blood Cancer Journal

Volumn 1, Issue 12, 2011, Pages

  Derenzini, E ^a   Lemoine, M ^a   Buglio, D ^a   Katayama, H ^a   Ji, Y ^a   Davis, R E ^a   Sen, S ^a   Younes, A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Aurora kinases; AZD1480; ERK; Hodgkin lymphoma; JAK2

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; INTERLEUKIN 13; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 3; RANTES; UO 126;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HODGKIN DISEASE; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; TH2 CELL; TUMOR IMMUNITY;

EID: 84863948323     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.57p     Document Type: Erratum

References (38)

1. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010; 221: 248-263.
2. Baus D, Pfitzner E. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer 2006; 118: 1404-1413.
3. Holtick U, Vockerodt M, Pinkert D, Schoof N, Sturzenhofecker B, Kussebi N et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 2005; 19: 936-944. (Pubitemid 40862003)
4. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283-4297. (Pubitemid 34627193)
5. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
6. Rui L, Emre NCT, Kruhlak MJ, Chung H-J, Steidl C, Slack G et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010; 8: 590-605.
7. Levy DE, Darnell Jr JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662. (Pubitemid 34987786)
8. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008; 112: 1424-1433.
9. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268-3277.
10. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-3029.
11. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008; 105: 20852-20857.
12. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111: 3220-3224.
13. Yamamoto R, Nishikori M, Tashima M, Sakai T, Ichinohe T, Takaori-Kondo A et al. B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci 2009; 100: 2093-2100.
14. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A et al. The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors. Cancer Cell 2009; 16: 487-497.
15. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011; 25: 538-550.
16. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma 1993; 9: 1-25. (Pubitemid 23141035)
17. Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy- geldanamycin in Hodgkin0s lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006; 12: 584-590. (Pubitemid 43166153)
18. Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019-1027. (Pubitemid 36917799)
19. Cochet O, Frelin C, Peyron J-F, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 2006; 18: 449-455. (Pubitemid 41790365)
20. Chatti K, Farrar WL, Duhe RJ. Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry 2004; 43: 4272-4283. (Pubitemid 38445648)
21. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917-921. (Pubitemid 27289594)
22. Boyle K, Zhang JG, Nicholson SE, Trounson E, Babon JJ, McManus EJ et al. Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS boxdependent regulation of JAK but not STAT phosphorylation. Cell Signal 2009; 21: 394-404.
23. Kamezaki K, Shimoda K, Numata A, Haro T, Kakumitsu H, Yoshie M et al. Roles of Stat3 and ERK in G-CSF signaling. Stem Cells 2005; 23: 252-263. (Pubitemid 40239520)
24. Dance M, Montagner A, Salles JP, Yart A, Raynal P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal 2008; 20: 453-459.
25. Ohtani T, Ishihara K, Atsumi T, Nishida K, Kaneko Y, Miyata T et al. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3-and SHP2-mediated signals in immune responses. Immunity 2000; 12: 95-105. (Pubitemid 30069218)
26. Forrai A, Boyle K, Hart AH, Hartley L, Rakar S, Willson TA et al. Absence of suppressor of cytokine signalling 3 reduces selfrenewal and promotes differentiation in murine embryonic stem cells. Stem Cells 2006; 24: 604-614. (Pubitemid 44464764)
27. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/ Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769-776.
28. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 2006; 66: 9509-9518. (Pubitemid 44623649)
29. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
30. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003; 170: 3369-3376. (Pubitemid 36302216)
31. Moriai S, Takahara M, Ogino T, Nagato T, Kishibe K, Ishii H et al. Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T-cell lymphoma cells. Clin Cancer Res 2009; 15: 6771-6779.
32. Baus D, Nonnenmacher F, Jankowski S, Doring C, Brautigam C, Frank M et al. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 2009; 23: 1885-1893.
33. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R et al. Inhibitor hijacking of Akt activation. Nat Chem Biol 2009; 5: 484-493.
34. Wong M, Uddin S, Majchrzak B, Huynh T, Proudfoot AE, Platanias LC et al. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 276: 11427-11431.
35. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-854. (Pubitemid 37411723)
36. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010; 115: 5202-5213.
37. Tomita M, Mori N. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci 2010; 101: 1204-1211.
38. Tomita M, Tanaka Y, Mori N. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro. Int J Cancer 2010; 127: 1584-1594.